Holen Sie sich die Stockscreener-App
6.97
0.43%
-0.03
Handel nachbörslich:
7.00
0.03
+0.43%
Schlusskurs vom Vortag:
$7.00
Offen:
$6.94
24-Stunden-Volumen:
768.44K
Relative Volume:
0.28
Marktkapitalisierung:
$411.98M
Einnahmen:
$216.11M
Nettoeinkommen (Verlust:
$-220.47M
KGV:
-1.8655
EPS:
-3.7363
Netto-Cashflow:
$-110.44M
1W Leistung:
+4.81%
1M Leistung:
-11.66%
6M Leistung:
+29.07%
1J Leistung:
+68.36%
1-Tages-Spanne:
$6.81
$7.04
1-Wochen-Bereich:
$6.595
$7.1998
52-Wochen-Spanne:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.97 | 413.76M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Rate Cut: Is Vanda Pharmaceuticals Inc affected by consumer sentimentStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Downgrade Watch: Can Vanda Pharmaceuticals Inc ride the EV waveDip Buying & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel - Investing.com Australia
Vanda Announces Resignation of Senior Legal Executive - TipRanks
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda - TradingView
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - stocktitan.net
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
VNDA Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Levels: Can Vanda Pharmaceuticals Inc ride the EV wavePortfolio Return Report & Low Risk Investment Opportunities - baoquankhu1.vn
Pullback Watch: Will Vanda Pharmaceuticals Inc outperform tech stocksRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update - MarketBeat
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA) - Stock Titan
Truist reiterates Vanda Pharmaceuticals stock rating after EMA decision By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageHere's Why - marketbeat.com
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - MarketScreener
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - stocktitan.net
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerat - GuruFocus
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - Bitget
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods – Company AnnouncementFT.com - Financial Times
Hedge Fund Moves: Is Vanda Pharmaceuticals Inc a strong candidate for buy and holdSwing Trade & Low Risk Entry Point Guides - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Gap UpTime to Buy? - MarketBeat
Growth Report: Will Vanda Pharmaceuticals Inc outperform tech stocks2026 Decliners & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanda Pharmaceuticals Stock (ISIN: US92178N1054) Faces Heightened Scrutiny Amid Pipeline Setbacks an - AD HOC NEWS
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
CEO Moves: Why is Vanda Pharmaceuticals Inc stock going up2026 Market Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag - Yahoo Finance
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - The Globe and Mail
Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada
VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView
Vanda Pharmaceuticals (VNDA) price target increased by 15.96% to 13.90 - MSN
Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug - Stock Titan
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vanda Pharmaceuticals Inc-Aktie (VNDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):